Diagnosis, Management, and Monitoring of IBD: Early Diagnosis and Individualizing Therapy

Diagnosis, Management, and Monitoring of IBD: Early Diagnosis and Individualizing Therapy

ReachMD Healthcare Image

How can clinicians earlier diagnose IBD in patients and create a personalized approach to treatment? Tune in.

Available credits: 0.25

Time to complete: 30 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    An expert in IBD discusses the latest in early diagnosis, individualizing therapy, and monitoring of IBD. Hear about early signs and symptoms of IBD as well as strategies for individualizing initial therapy in patients with IBD based on available agents and guidelines. 

  • Disclosure of Conflicts of Interest

    All faculty and planners participating in continuing education activities sponsored by Partners for Advancing Clinical Education (PACE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PACE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis. 

    Bruce E. Sands, MD, MS: consultant/advisor/speaker: AbbVie, Amgen, Arena Pharmaceuticals, AstraZeneca, Boehringer-Ingelheim, Bristol Myers Squibb, Celltrion, Fresenius Kabi, Genentech, GlaxoSmithKline, Janssen, Lilly, Merck, Pfizer, Sun Pharma, Takeda, Teva.

    The planners and content peer reviewers from Partners for Advancing Clinical Education, the American Gastroenterological Associate, Practicing Clinicians Exchange, and Clinical Care Options, LLC do not have any relevant financial relationships to disclose, except Kimberly Kearns, MS, APN-BC as noted below: 

    Kimberly Kearns, MS, APN-BC: consultant/advisor/speaker: Lilly, Janssen, Salix

  • Target Audience

    This program is intended for the IBD care team including gastroenterologists, advanced practice providers that specialize in gastroenterology, internal medicine and family medicine physicians and advanced practice providers, nurses and other HCPs involved in the care of patients living with IBD.

  • Learning Objectives

    Upon completion of this activity, participants should be able to:

    • Describe early signs and symptoms of IBD to prevent delays in diagnosis and treatment initiation
    • Implement strategies for individualizing initial therapy in patients with IBD based on available agents and guidelines
  • Accreditation and Credit Designation Statements

    Accreditation Statement
    The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Credit Designation
    The AGA Institute designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Joint Accreditation Statement

    In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

    ANCC Credit Designation
    Nursing contact hours: 0.25 , which includes 0.25  hour of pharmacology credit
    Nurse Course Advisor: Kimberly Kearns, MS, APN-BC, Duly Health and Care, Hoffman Estates, Illinois

    AAPA Credit Designation

    Partners in Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until January 24, 2024. PAs should only claim credit commensurate with the extent of their participation. 

    PA Course Advisor: Abigail Meyers, PA-C, Mayo Clinic, Rochester, Minnesota

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

  • Provider(s)/Educational Partner(s)

    Provided by AGA and PACE in partnership with CCO and PCE

  • Commercial Support

    This educational activity is supported by educational grants from Amgen, Inc.; Ferring Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments


We’re glad to see you’re enjoying Crohn's Colitis Professional…
but how about a more personalized experience?

Register for free